Institute of Cardiometabolism and Nutrition, France
12
2
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.3%
1 terminated/withdrawn out of 12 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in Cirrhosis
Role: collaborator
Global Research Initiative for Patients Screening on MASH
Role: collaborator
The European NAFLD Registry
Role: collaborator
NASH and Coronary Disease
Role: collaborator
Developing Derived Induced Pluripotent Stem Cells as a Model to Understand Imprinted Disorders
Role: lead
Study of Coronary Calcification in Subjects With Autosomal Dominant Familial Hypercholesterolemia Heterozygous
Role: collaborator
Intestinal Permeability in Obesity
Role: collaborator
Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions
Role: collaborator
Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging
Role: collaborator
Retina Microvascular Remodeling and Cognitive Function In Hypertension
Role: lead
MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)
Role: lead
Effect of the Alpha-galacto-oligasaccharides on Weight Loss in Overweight or Moderately Obeses Adults : A Randomized Controlled Double Blinded Trial Versus Placebo
Role: collaborator
All 12 trials loaded